Immatics N.V. develops clinical-stage cancer immunotherapies built around T-cell receptor biology, with a stated focus on precision targeting of PRAME across solid tumors. News about IMTX most often covers clinical updates for PRAME-directed cell therapies and TCR bispecifics, including anzu-cel (anzutresgene autoleucel, IMA203), IMA203CD8, IMA402 and IMA401 MAGEA4/8. Company announcements also cover presentations at oncology meetings such as ASCO, AACR and ESMO, where Immatics reports safety, dose-escalation and anti-tumor activity data across melanoma, ovarian cancer, synovial sarcoma and other PRAME-positive cancers.
Recurring updates include financial results, business updates, collaboration activity, clinical and regulatory disclosures, leadership changes, shareholder voting matters and capital-structure disclosures for the Nasdaq-listed biotechnology company.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.